High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The use of daptomycin in Gram-positive left-sided infective endocarditis (IE) has significantly increased. The purpose of this study was to assess the influence of high-dose daptomycin on the outcome of left-sided IE due to Gram-positive pathogens. This was a prospective cohort study based on 1,112 cases from the International Collaboration on Endocarditis (ICE)-Plus database and the ICE-Daptomycin Substudy database from 2008 to 2010. Among patients with left-sided IE due to Staphylococcus aureus , coagulase-negative staphylococci, and Enterococcus faecalis , we compared those treated with daptomycin (cohort A) to those treated with standard-of-care (SOC) antibiotics (cohort B). The primary outcome was in-hospital mortality. Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. There were 29 and 149 patients included in cohort A and cohort B, respectively. Baseline comorbidities did not differ between the two cohorts, except for a significantly higher prevalence of diabetes and previous episodes of IE among patients treated with daptomycin. The median daptomycin dose was 9.2 mg/kg of body weight/day. Two-thirds of the patients treated with daptomycin had failed a previous antibiotic regimen. In-hospital and 6-month mortalities were similar in the two cohorts. In cohort A, median time to clearance of methicillin-resistant S. aureus (MRSA) bacteremia was 1.0 day, irrespective of daptomycin dose, representing a significantly faster bacteremia clearance compared to SOC (1.0 versus 5.0 days; P < 0.01). Regimens with higher daptomycin doses were not associated with increased incidence of AEs. In conclusion, higher-dose daptomycin may be an effective and safe alternative to SOC in the treatment of left-sided IE due to common Gram-positive pathogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in an observational study, high-dose daptomycin (≈9 mg/kg per dose) for treatment of left-sided IE was as effective as standard-of-care therapy and cleared MRSA bacteremia significantly faster than did standard-ofcare treatment.155”
In the citing paper
“The emergence of organisms with decreased susceptibility to daptomycin was observed in ≈5% of daptomycin-treated patients.”
Citations
Cites
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Self-citationDurack, D. T., Lukes, A. S., Bright, D. K., & Service, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90143-0 · Cited by 2,572 · cited 1×
““Persistent bacteremia” was defined using Duke Endocarditis Service Criteria as persistence of positive blood cultures after 72 h of organism-specific targeted antibacterial treatment (22).”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Self-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationAntibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
Arias, C. A., & Murray, B. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0804651 · Cited by 1,027 · cited 1×
“Additionally, the rate of antimicrobial resistance among common Gram-positive IE pathogens has increased (5, 6), creating an urgent need for antibiotics with activity against such resistant pathogens.”
BackgroundContemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis
Wang, A. (2007) · JAMA · doi:10.1001/jama.297.12.1354 · Cited by 703
Self-citationThe Perpetual Challenge of Infectious Diseases
Fauci, A. S., & Morens, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108296 · Cited by 517 · cited 1×
“Additionally, the rate of antimicrobial resistance among common Gram-positive IE pathogens has increased (5, 6), creating an urgent need for antibiotics with activity against such resistant pathogens.”
BackgroundCui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Temporal Trends in Infective Endocarditis in the Context of Prophylaxis Guideline Modifications
Duval, X., Delahaye, F., Alla, F., Tattevin, P., Obadia, J.-F., Le Moing, V., Doco-Lecompte, T., Celard, M., Poyart, C., Strady, C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.029 · Cited by 383
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Self-citationHabib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citation2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Self-citationClinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
“Levine et al,45 1991 (openlabel RCT) Moderate 42 MRSA endocarditis (median [range] age of 32 [23-61] y); treatment with vancomycin alone (1 g every 12 h; n = 22) vs vancomycin (1 g every 12 h) plus rifampin (600 mg/d) (n = 20) Duration of bacteremia Median duration of 9 d for bacteremia for all patients; 7 (95% CI, 5…”
Self-citationHolland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Self-citationSandoe, J. A. T., Barlow, G., Chambers, J. B., Gammage, M., Guleri, A., Howard, P., Olson, E., Perry, J. D., Prendergast, B. D., Spry, M. J., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku383 · Cited by 403
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Self-citationBeganovic, M., Luther, M. K., Rice, L. B., Arias, C. A., Rybak, M. J., & LaPlante, K. L. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy064 · Cited by 234
Infective Endocarditis: A Contemporary Review
Hubers, S. A., DeSimone, D. C., Gersh, B. J., & Anavekar, N. S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.008 · Cited by 200
JCS 2017 Guideline on Prevention and Treatment of Infective Endocarditis
Nakatani, S., Ohara, T., Ashihara, K., Izumi, C., Iwanaga, S., Eishi, K., Okita, Y., Daimon, M., Kimura, T., Toyoda, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0549 · Cited by 179
2015 ESC Guidelines for the management of infective endocarditis
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0227 · Cited by 165
Self-citationCandida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy
Arnold, C. J., Johnson, M., Bayer, A. S., Bradley, S., Giannitsioti, E., Miró, J. M., Tornos, P., Tattevin, P., Strahilevitz, J., Spelman, D., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04867-14 · Cited by 110
Self-citationvan Duijkeren, E., Schwarz, C., Bouchard, D. S., Catry, B., Pomba, C., Baptiste, K. E., Moreno, M. Á., Rantala, M. H. J., Ružauskas, M., Sandérs, P., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz161 · Cited by 106
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections
Hamed, K. A., González-Ruiz, A., & Seaton, A. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s99046 · Cited by 104
Turnidge, J. D., Kahlmeter, G., Cantón, R., MacGowan, A. P., & Giske, C. G. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.027 · Cited by 92
Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 81
Luther, M. K., Arvanitis, M., Mylonakis, E. E., & LaPlante, K. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02790-13 · Cited by 79
“02).(65) Although small, this study also demonstrated no significant increase in adverse 331 events with higher dose daptomycin.”
ResultGudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
Self-citationAminoglycosides for infective endocarditis: time to say goodbye?
Lebeaux, D., Fernández‐Hidalgo, N., Pilmis, B., Tattevin, P., & Mainardi, J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.017 · Cited by 74
Self-citationSeaton, R. A., Menichetti, F., Dalekos, G., Beiras-Fernández, A., Nacinovich, F., Pathan, R. B., & Hamed, K. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0267-4 · Cited by 72
“Furthermore, high-dose daptomycin was shown to be an effective and safe alternative to standard-of-care in the treatment of left-sided endocarditis due to common Gram-positive pathogens [15, 16].”
BackgroundSelf-citationWhat’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J., Zotti, F. D., Dulgheru, R., Khoury, G. A. E., Erba, P. A., Iung, B., et al. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.11.015 · Cited by 54
Self-citationBacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus
Bergin, S. P., Holland, T. L., Fowler, V. G., & Tong, S. Y. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_5001 · Cited by 50
Self-citationPasquaroli, S., Citterio, B., Cesare, A. D., Amiri, M., Manti, A., Vuotto, C., & Biavasco, F. (2014) · Pathogens · doi:10.3390/pathogens3030759 · Cited by 48
“The success of multidrug-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) [5–7], vancomycin-resistant enterococci (VRE) [8] and coagulase-negative staphylococci [9], emphasizes the need for new antimicrobials with alternative mechanisms of action.”
BackgroundBhavnani, S. M., Ambrose, P. G., Hammel, J., Rubino, C. M., & Drusano, G. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02967-15 · Cited by 46
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
Munita, J. M., Murray, B. E., & Arias, C. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.08.002 · Cited by 45
Tzoumas, A., Sagris, Μ., Xenos, D., Ntoumaziou, A., Kyriakoulis, I., Kakargias, F., Liaqat, W., Nagraj, S., Patel, R., Korosoglou, G., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.023 · Cited by 44
High-Dose Daptomycin and Clinical Applications
Jones, T. W., Jun, A. H., Michal, J. L., & Olney, W. J. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028021991943 · Cited by 42
Falcone, M., Russo, A., & Venditti, M. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.012 · Cited by 41
Snyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41
Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data
Senneville, É., Caillon, J., Calvet, B., & Jehl, F. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.11.005 · Cited by 39
Mistiaen, W. P. (2018) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2018.1433318 · Cited by 39
“[4,9,15,19,23,33], treatment bias [14,30] and survivor bias,”
BackgroundMethodInfluentialTimbrook, T. T., Caffrey, A. R., Luther, M. K., Lopes, V., & LaPlante, K. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2070 · Cited by 39
Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
Durante‐Mangoni, E., Andini, R., Parrella, A., Mattucci, I., Cavezza, G., Senese, A., Trojaniello, C., Caprioli, R., Diana, M. V., & Utili, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.022 · Cited by 35
“Also, the actual number of IE patients included in these studies was limited, ranging from 15 to 70 [14–19].”
BackgroundSelf-citationShafiq, I., Bulman, Z. P., Spitznogle, S. L., Osorio, J., Reilly, I. S., Lesse, A. J., Parameswaran, G. I., Mergenhagen, K. A., & Tsuji, B. T. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1277587 · Cited by 34
Hidalgo, L. H., de Alarcón, A., López-Cortés, L. E., Márquez, R. L., López-Cortés, L. E., Gutiérrez‐Valencia, A., & Gil-Navarro, M. V. (2020) · Antibiotics · doi:10.3390/antibiotics9100657 · Cited by 32
“The majority of studies included left- and right-sided endocarditis, with the exception of three studies treating only left-sided IE [12,28,33].”
BackgroundMethodResultInfluentialHigh-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It
Smith, J. R., Claeys, K. C., Barber, K. E., & Rybak, M. J. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0429-6 · Cited by 31
“Clinical data suggest more rapid clearance of bacteremia with daptomycin compared to vancomycin as well, as studies demonstrate bacteremia clearance with daptomycin to be 1 to 4 days faster than with vancomycin [28, 29].”
He, W., Zhang, Y., Chen, H., Zhao, C., & Wang, H. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku277 · Cited by 29
Adamu, Y., Puig‐Asensio, M., Dabo, B., & Schweizer, M. L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293423 · Cited by 28
“One study excluded all patients with endocarditis [24], while another study exclusively recruited endocarditis patients [32].”
BackgroundResultGonzález-Ruiz, A., Gargalianos-Kakolyris, P., Timerman, A., Sarma, J., Ramallo, V. J. G., Bouylout, K., Trostmann, U., Pathan, R. B., & Hamed, K. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0220-6 · Cited by 26
“In addition, the rapid bactericidal activity of daptomycin is expected to reduce the opportunity for development of potential resistance [18, 21, 27, 28].”
BackgroundDiagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*
Yavuz, S. Ş., Akar, A. R., Aydoğdu, S., Deniz, D. B., Demir, H., Hazırolan, T., Ozatik, M. A., Özer, N., Sargın, M., Topçuoğlu, N., et al. (2020) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2020.89689 · Cited by 25
Guleri, A., Utili, R., Dohmen, P. M., Petrosillo, N., Piper, C., Pathan, R. B., & Hamed, K. A. (2015) · Infectious Diseases and Therapy · doi:10.1007/s40121-015-0075-9 · Cited by 23
“This was consistent with a previous report [21].”
ResultShould High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?
Peghin, M., Russo, A., Givone, F., Ingani, M., Graziano, E., & Bassetti, M. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00261-w · Cited by 22
Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci
Leone, S., Noviello, S., & Esposito, S. (2015) · Infection · doi:10.1007/s15010-015-0836-0 · Cited by 22
Pericàs, J. M., García-de-la-Mària, C., Brunet, M., Armero, Y., García-González, J. A., Casals, G., Almela, M., Quintana, E., Falces, C., Ninot, S. P. I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx016 · Cited by 21
Self-citationSamura, M., Hirose, N., Kurata, T., Takada, K., Nagumo, F., Koshioka, S., Ishii, J., Uchida, M., Inoue, J., Enoki, Y., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab568 · Cited by 20
Analysis of the 2015 American and European guidelines for the management of infective endocarditis
Tattevin, P., & Mainardi, J. (2016) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.05.008 · Cited by 21
Samura, M., Takada, K., Hirose, N., Kurata, T., Nagumo, F., Uchida, M., Inoue, J., Tanikawa, K., Enoki, Y., Taguchi, K., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15671 · Cited by 18
“Fifth, the analysis in the present study included studies evaluating Gram-positive cocci infections, such as methicillin-susceptible S. aureus, coagulase-negative staphylococci and enterococci other than MRSA.”
BackgroundInfluentialHaynes, A. S., Maples, H. D., & Parker, S. K. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad032 · Cited by 18
Sader, H. S., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.04.003 · Cited by 17
Samura, M., Takada, K., Hirose, N., Kurata, T., Nagumo, F., Koshioka, S., Ishii, J., Uchida, M., Inoue, J., Enoki, Y., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15172 · Cited by 16
Daptomycin-Containing Regimens for Treatment of Gram-Positive Endocarditis
Russo, A., Peghin, M., Givone, F., Ingani, M., Graziano, E., & Bassetti, M. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.011 · Cited by 14
Linee guida ESC 2023 per il trattamento dell’endocardite
Marsan, N. A., de Waha, S., Bonaros, N. E., Brida, M., Burri, H., Caselli, S., Doenst, T., Éderhy, S., Erba, P. A., Foldager, D., et al. (2023) · Giornale Ialiano di Cardiologia · doi:10.1714/4144.41413 · Cited by 13
Self-citationPossible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review
Mo, Y., Nehring, F., Jung, A. H., & Housman, S. T. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190015625403 · Cited by 13
“Despite concern for muscle toxicity, recent studies have shown that daptomycin is well tolerated at these high doses.(3,4) We identified a total of 7 cases reporting daptomycin-induced hepatotoxicity.”
BackgroundYavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Infective Endocarditis in Patients Receiving Hemodialysis: A Current Review
Ding, U., Ooi, L., Wu, H. H. L., & Chinnadurai, R. (2024) · Kidney Diseases · doi:10.1159/000540513 · Cited by 11
Sánchez, M. Á. G., Urkola, X. K., Santiago, E. B., Muñóz, P., Moreno, E. V., Fariñas, M. C., Cobo, R. T., Pericàs, J. M., González, A. D. A., Regueiro, D. S., et al. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.03.009 · Cited by 11
Matsuo, T., Mori, N., Sakurai, A., Kanie, T., Mikami, Y., Uehara, Y., & Furukawa, K. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01113 · Cited by 11
“Subsequently, it had been widely used not only for right-sided endocarditis but also for left-sided endocarditis based upon several clinical trials [8].”
BackgroundA retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin
Hermsen, E. D., Mendez-Vigo, L., Berbari, E. F., Chung, T., Yoon, M., & Lamp, K. C. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1590-3 · Cited by 10
Balda, J., Alpizar-Rivas, R. M., Elarabi, S., Jaber, B. L., & Nader, C. M. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.07.009 · Cited by 10
New advances in management and treatment of cardiac implantable electronic devices infections
Russo, A., Serraino, R., Serapide, F., Trecarichi, E. M., & Torti, C. (2023) · Infection · doi:10.1007/s15010-023-02130-8 · Cited by 9
“…left-sided IE, high-dose daptomycin was not significantly associated with any difference for in-hospital mortality compared with standard of care [60], and these data were confirmed also in other studies [61] Some recent articles have evaluated the efficacy of daptomycin combined with other…”
ResultMinotti, C., Zuccon, I., Priante, E., Bonadies, L., Chiara, C. D., Donà, D., Baraldi, E., & Costenaro, P. (2022) · Children · doi:10.3390/children9040457 · Cited by 9
“[13] 2011 1, 27 4/7 980 MRSA Bacteremia 10 mg/kg once daily, then 15 mg/kg once daily 14 days No Recovered and discharged (No relapse at 6-month follow-up)”
BackgroundAetiology of renal failure in patients with infective endocarditis. The role of antibiotics
Sánchez, M. Á. G., Urkola, X. K., Santiago, E. B., García, P. M., Moreno, E. V., Fariñas, M. C., Cobo, R. T., Pericàs, J. M., González, A. D. A., Regueiro, D. S., et al. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.09.006 · Cited by 9
Xu, P., Zeng, H., Zhou, M., Ouyang, J., Chen, B., & Zhang, Q. (2017) · Medicine · doi:10.1097/md.0000000000009451 · Cited by 9
Guleri, A., Utili, R., Dohmen, P. M., & Hamed, K. A. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936117692297 · Cited by 9
Corcione, S., Lupia, T., Pallotto, C., Giacobbe, D. R., Benedetto, I. D., Stroffolini, G., Pinna, S. M., Tascini, C., Bassetti, M., Rosa, F. G. D., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11010056 · Cited by 8
“Considering daptomycin in IE treatment represents an option to encourage aminoglycoside and glycopeptide sparing strategy in order to avoid renal damage, especially in elderly comorbid population [12,13].”
BackgroundSandoval, N., Grau, S., Sorlí, L., Montero, M., Esteve, E., & Horcajada, J. P. (2015) · Future Microbiology · doi:10.2217/fmb.15.41 · Cited by 8
Ross, J. K., Rankin, S., Marshik, P. L., Mercier, R.-C., Brett, M., & Walraven, C. J. (2015) · Antibiotics · doi:10.3390/antibiotics4030309 · Cited by 8
How to manage patients in whom malignancy and infective endocarditis are associated: a review
Mistiaen, W. P., & Gebruers, N. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1698762 · Cited by 7
“While the effect of a malignancy in IE on outcome received attention, the presence of such infected cardiac device is either not analyzed of specified in most series [32,40,41,44].”
BackgroundFactors Associated with Daptomycin-Induced Eosinophilic Pneumonia
Ishikawa, K., Matsuo, T., Tsuda, Y., Rahman, M., Uehara, Y., & Mori, N. (2022) · Antibiotics · doi:10.3390/antibiotics11020254 · Cited by 7
“DAP is bactericidal and is considered to be more effective than VCM for MRSA infections; this was observed in a previous study where a higher the duration of negative blood cultures was observed with DAP than VCM [4].”
ResultJCS 2026 Guideline on the Management of Infective Endocarditis
Izumi, C., Daimon, M., Kaji, S., Masumoto, A., Ashihara, K., Amano, M., Uemura, S., Ota, H., Ohara, T., Okada, K., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-0987 · Cited by 7
Gregori, S. D., SILVESTRI, A. D., Capone, M., Monzillo, V., Giordani, P., Bruno, R., & Seminari, E. M. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241296232 · Cited by 6
A case report and literature review of daptomycin-induced liver injury
Markmann, A. J., & Jogendra, M. R. D. (2018) · IDCases · doi:10.1016/j.idcr.2018.e00452 · Cited by 6
Schrenk, K. G., Frosinski, J., Scholl, S., Otto, S., Rosée, P. G. L., Hochhaus, A., & Pletz, M. W. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2526-5 · Cited by 5
Infektiöse Endokarditis: Neue Leitlinien 2015
Plicht, B., Lind, A. Y., & Erbel, R. (2016) · Der Internist · doi:10.1007/s00108-016-0086-y · Cited by 5
“Daptomycin hat den Vorteil, wirksamer als Vancomycin gegen methicillinsensible und vergleichbar wirksam wie Vancomycin gegen methicillinresistente Staphylokokkenstämme zu sein [20].”
Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan
Ebihara, F., Hamada, Y., Kato, H., Maruyama, T., & Kimura, T. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052516 · Cited by 5
Pharmacodynamics of Daptomycin
Wenzler, E., Liao, S., & Rodvold, K. A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_13 · Cited by 4
Khoury, A., & Rattanasuwan, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.endocarditis_overview · Cited by 4
Donnelly, J., McDermott, H., Gash, S., O'Connor, C., O’Connell, K., O’Donnell, S., Dinesh, B., Burns, K., & Fitzpatrick, F. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.02.018 · Cited by 3
Shigeta, H., Tanaka, K., Hoshina, T., & Kusuhara, K. (2021) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2021.03.007 · Cited by 3
Policarpo, S. N., Duro, R. P., Rocha-Pereira, N., & Santos, L. (2024) · Cureus · doi:10.7759/cureus.54134 · Cited by 3
“Daptomycin has shown non-inferiority compared to vancomycin in complicated BSI and IE by MRSA and MR-CoNS [17-19].”
BackgroundInfective Endocarditis Following Chicken Pox: A Rare Association
Bhatt, M., Gupta, N. R., Soneja, M., Das, U., Velpandian, T., & Biswas, A. (2019) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms662004 · Cited by 3
Ghadaki, B., & Yamamura, D. L. R. (2018) · Wiley eBooks · doi:10.1002/9781119260363.ch4 · Cited by 3
Saany, M. A., & Jahangiri, A. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103264 · Cited by 2
Vinh, D. C., & Embil, J. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27784-4_9 · Cited by 2
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Perera, V., Wardlow, L. C., Sobhanie, M. M., Coe, K. E., & Leininger, J. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11697-6 · Cited by 1
“These results are consistent with previous studies [4, 6].”
InfluentialLanier, K., Jawanda, J. S., & Cid, A. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf227 · Cited by 1
Drake, S., Leininger, J., Bazan, J. A., Coe, K. E., & Wardlow, L. C. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag179 · Cited by 1
Slim, J., Jimenez, H. R., Culshaw, D. L., Patel, H. N., & Lamp, K. C. (2014) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957414553840 · Cited by 1
“5 (5-28) days; bone and joint infection, 26 (12-94) days; endocarditis, 28 (7-61) days; SSSI, 10 (1-46) days; and UTI/ pyelonephritis, 9.”
Loron, S., Dulac, A., Jegaden, O., & Ferry, T. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-206907 · Cited by 1
Treating endocarditis: A protocol of an antimicrobal treatment from a middle-income country
Barbosa, G. F., Zappa, B. C., Garrido, R. Q., & Lamas, C. D. C. (2018) · Heart Vessels and Transplantation · doi:10.24969/hvt.2018.65 · Cited by 1
Infective Endocarditis in the Current Clinical Practice
Горбич, Ю. Л., Карпов, И. А., Соловей, Н. В., & Горбич, О. А. (2020) · Клиническая инфектология и паразитология · doi:10.34883/pi.2020.9.1.009 · Cited by 1
Therapeutic Options for Resistant Gram Positives
Menon, V., & van Hal, S. J. (2014) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-014-0028-y
Tennant, S. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.298
Antibiothérapie des endocardites infectieuses : lecture critique des recommandations 2015
Tattevin, P. (2017) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2017.01.001
Methicillin-Resistant Staphylococcus aureus Endocarditis: Still Seeking for the Appropriate Therapy
Rodríguez-Noriega, E., & Morfín‐Otero, R. (2017) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000527
Actualización en la endocarditis sobre válvula protésica por Staphylococcus aureus
Bejar, S., & Maria, C. F. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Terapêutica Antibiótica de Associação Empírica e Dirigida das Endocardites
Lino, R. D. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/4kzp-sq77
Metadata
- Authors
- Carugati, M., Bayer, A. S., Miró, J. M., Park, L. P., Guimarães, A. C., Skoutelis, A., Fortes, C. Q., Durante-Mangoni, E., Hannan, M. M., Nacinovich, F., Fernández-Hidalgo, N., Grossi, P., Tan, R.-S., Holland, T., Fowler, V. G., Corey, R. G., & Chu, V. H.
- Affiliations
- University of Milan (IT)
- University of California, Los Angeles (US)
- Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
- Duke Medical Center (US)
- Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil
- Evangelismos Hospital (GR)
- Clementino Fraga Filho Hospital, Rio de Janeiro, Brazil
- University of Naples S.U.N., Monaldi Hospital, Naples, Italy
- Mater Misericordiae University Hospital (IE)
- Instituto Cardiovascular de Buenos Aires (AR)
- Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
- University of Insubria (IT)
- National Heart Centre Singapore (SG)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-12
- Volume
- 57
- Issue
- 12
- Pages
- 6213-6222
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3837915
- OpenAlex
- W1978437183
- Cited by
- 100
- References
- 30
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 11 · 2015: 19 · 2014: 11
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (K24AI093969)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- daptomycin, high-dose daptomycin, left-sided endocarditis, Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, bacteremia clearance, in-hospital mortality, adverse events, antibiotic treatment failure
- MeSH terms
- Aged, Anti-Bacterial Agents, Endocarditis, Bacterial, Female, Humans, Male, Middle Aged, Prospective Studies, Staphylococcus aureus, Enterococcus faecalis, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.